CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
MT-7117 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04440592
NCT04440592Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Tanabe Pharma America, Inc.·interventional·Posted Jun 19, 2020·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating MT-7117 and Placebo for Diffuse Cutaneous Systemic Sclerosis. Completed, enrolled 76 participants across 34 sites in 8 countries.

Detailed Summary

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Cutaneous Systemic Sclerosis
CountriesBelgium, Canada, Germany, Italy, Poland, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 19, 2020
Enrollment StartFeb 5, 2021
Primary CompletionJan 17, 2024
Study CompletionFeb 14, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.0 years ago

Interventions

MT-7117drug

MT-7117

Placebodrug

Placebo